Fierce Pharma

JANUARY 19, 2023

Bluebird extends cash runway to late 2024 with $113M raise through stock sale esagonowsky Thu, 01/19/2023 - 08:30

Sales 305

Sales 305

Fierce Pharma

OCTOBER 29, 2024

As the 2024 U.S. This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy.

246

246

Fierce Pharma

FEBRUARY 1, 2024

On both fronts, Sanofi expects to see dividends in 2024. . | As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial respiratory launch with partner AstraZeneca.

298

298

Fierce Pharma

JANUARY 4, 2024

In 2024, CDMOs can advance their priorities on three fronts, a group of experts said during a recent Evaluate webinar on the state of the industry. Even after the heady highs of the COVID-19 era, the contract development and manufacturing organization (CDMO) realm remains one of biopharma's buzziest fields.

Biopharma 299

Biopharma Manufacturing 299

Fierce Pharma

AUGUST 30, 2024

ESC 2024: UK's George Medicines posts positive results for triple-combo blood pressure drug on heels of FDA submission fkansteiner Fri, 08/30/2024 - 15:54

Medicine 264

Medicine FDA 264

Fierce Pharma

OCTOBER 22, 2024

With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one. Following a string of high-profile deals, Samsung Biologics has locked down a $1.2 billion contract with an unnamed Asia-based pharmaceutical company that’s expected to run through December 2037.

Pharmaceutical 316

Pharmaceutical 316

Fierce Pharma

JANUARY 9, 2023

JPM23: Bluebird touts gene therapy launch progress, extends cash runway to 2024. esagonowsky. Mon, 01/09/2023 - 09:26.

272

272

Fierce Pharma

AUGUST 5, 2024

Join us at Digital Pharma East 2024 on Sept. The pharmaceutical industry is in a constant state of evolution, driven by technological advancements, shifting consumer behaviors, and a complex regulatory landscape. 9-12 in Philadelphia to learn, connect, and innovate with your life sciences marketing industry peers.

Pharma 212

Pharma Marketing Pharmaceutical 212

Fierce Pharma

MAY 2, 2024

WuXi Biologics has withdrawn from the 2024 BIO International Convention as the U.S. . | Japan's Ono will buy kinase inhibitor expert Deciphera for $2.4 Novartis invests further in radiopharmaceuticals with two deals. grows hostile against certain Chinese biotech companies. And more.

Pharma 246

Pharma Pharmaceutical 246

Fierce Pharma

FEBRUARY 8, 2024

This week on “The Top Line,” we explore the most anticipated drug launches of 2024. This week on “The Top Line,” we explore the most anticipated drug launches of 2024.

Sales 189

Sales Pharma Marketing 189

Fierce Pharma

JANUARY 9, 2024

Speaking to reporters at the 2024 J.P. Speaking to reporters at the 2024 J.P. Pfizer knows it had a bad year in 2023. Pfizer knows it had a bad year in 2023.

Healthcare 349

Healthcare Healthcare 349

Fierce Pharma

AUGUST 16, 2024

It’s time once again to nominate the fiercest women you know in the life science industry for our annual list. It’s time once again to nominate the fiercest women you know in the life science industry for our annual list.

316

316

Fierce Pharma

JANUARY 3, 2024

Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024. As the J.P. | As the J.P.

Biopharma 346

Biopharma Sales Healthcare Healthcare 346

Fierce Pharma

FEBRUARY 28, 2024

As Novavax emerges from its “transition year” in 2023, the vaccine maker is still raising concerns among Wall Street investors in early 2024. | As Novavax emerges from its “transition year” in 2023, the vaccine maker is still raising concerns among Wall Street investors in early 2024.

298

298

Fierce Pharma

AUGUST 8, 2024

While a glut of drugmakers have raised their 2024 financial guidance after the second quarter, those upgraded sales expectations pale in comparison to Eli Lilly’s new forecast for the year. billion in 2024. Lilly, which reported a 36% sales increase year-over-year to $11.3 All told, the company now expects to rake in sales between $45.5

Sales 312

Sales 312

Fierce Pharma

OCTOBER 2, 2024

Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility fkansteiner Wed, 10/02/2024 - 07:31

Manufacturing 328

Manufacturing 328

Fierce Pharma

NOVEMBER 22, 2024

As other Big Pharmas face local headwinds, Pfizer doubles down on China commitment with Zai Lab antimicrobial marketing pact fkansteiner Fri, 11/22/2024 - 09:04

Marketing 290

Marketing Pharma 290

Fierce Pharma

FEBRUARY 1, 2024

After GSK spent the latter half of 2023 warding off concerns about the swelling Zantac product liability litigation, the company is back at the settlement table in 2024. After GSK spent the latter half of 2023 warding off concerns about the swelling Zantac product liability litigation, the company is back at the settlement table in 2024.

296

296

Fierce Pharma

MARCH 26, 2024

buyout esagonowsky Tue, 03/26/2024 - 10:49 Bristol Myers Squibb cuts hundreds of Mirati staffers months after closing $5.8B

320

320

Fierce Pharma

APRIL 5, 2024

Inclusive Innovation: Key to the Future of Healthcare jpiatt Fri, 04/05/2024 - 10:37

Healthcare 312

Healthcare Healthcare 312

Fierce Pharma

NOVEMBER 13, 2024

Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years fkansteiner Wed, 11/13/2024 - 14:37

Patients 317

Patients 317

Fierce Pharma

JULY 22, 2024

At his vacation home in Delaware, President Joe Biden made the striking announcement that he is dropping out of the 2024 | While President Joe Biden is officially out for the 2024 election, his term has certainly made a mark in the healthcare realm.

Healthcare 278

Healthcare Healthcare 278

Fierce Pharma

JANUARY 30, 2024

kdunleavy Tue, 01/30/2024 - 08:58 After 'bad launch' remark by CEO, Pfizer's RSV vaccine gains traction in Q4. How will it fare in latest round of GSK showdown?

317

317

Fierce Pharma

FEBRUARY 14, 2024

FDA unleashes multiple warning letters targeting insanitary manufacturing and online sales of unapproved Mounjaro, Ozempic fkansteiner Wed, 02/14/2024 - 05:10

Manufacturing 306

Manufacturing Sales FDA 306

Fierce Pharma

OCTOBER 3, 2024

On its way to becoming the most highly anticipated approval of 2024, BMS’ schizophrenia treatment Cobenfy has had an unusual but instructive odyssey.

306

306

Fierce Pharma

MAY 6, 2024

With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward. As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey.

Sales 334

Sales Marketing 334

Fierce Pharma

OCTOBER 10, 2024

Activist investor Starboard accuses Pfizer of strong-arming former execs into backing CEO Bourla ahead of strategy meeting zbecker Thu, 10/10/2024 - 11:03

306

306

Fierce Pharma

SEPTEMBER 13, 2024

ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value added from new cancer approvals kdunleavy Fri, 09/13/2024 - 07:38

305

305

David Bagga

MAY 29, 2024

How Much Do Medical Device Sales Reps Make in 2024? Home Blog How Much Do Medical Device Sales Reps Make in 2024? How Much Do Medical Device Sales Reps Make in 2024? It’s […] The post How Much Do Medical Device Sales Reps Make in 2024? appeared first on.

Sales 130

Sales Medical Medical sales 130

MedCity News

JANUARY 19, 2024

AI, health equity and merger and acquisition activity are among the trends to watch in 2024, according to a recent report from Deloitte.

Healthcare 140

Healthcare Healthcare 140

David Bagga

MAY 29, 2024

In 2018, the average base salary of a medical sales representative was $92,698 How to Become A Medical Device Sales Rep in 2024? Home Blog How to Become A Medical Device Sales Rep in 2024? How to Become A […] The post How to Become A Medical Device Sales Rep in 2024? appeared first on.

Sales 130

Sales Medical Medical sales Marketing 130

MedCity News

JANUARY 5, 2024

As we look into the future, 2024 promises a profound transformation. Here are five areas of focus for the upcoming year.

Healthcare 130

Healthcare Healthcare 130

Fierce Pharma

JULY 9, 2024

Bayer’s massive reorganization championed by CEO Bill Anderson is bringing major changes to the German company’s pharma commercial team, shaking up its structure, personnel and operations. Bayer’s massive reorganization championed by CEO Bill Anderson is bringing major changes to the German company’s pharma commercial team.

Pharma 298

Pharma 298

Fierce Pharma

APRIL 11, 2024

as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001. As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. |

Biopharma 328

Biopharma Pharma 328

Fierce Pharma

MARCH 11, 2024

Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s multiple sclerosis (MS) drug Co | Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s (..)

FDA 278

FDA 278

Fierce Pharma

FEBRUARY 28, 2024

After a busy 2023 marked by multiple drug approvals, UCB isn’t resting on its laurels. After an initial FDA approval came later than anticipated, UCB is looking to quickly grow Bimzelx. The company is eying four new indications and potential peak sales of 4 billion euros.

FDA 305

FDA Sales 305

Fierce Pharma

JANUARY 3, 2024

When GSK laid out $90 million upfront to acquire rights to Scynexis’ antifungal Brexafemme last spring, the British pharma threw a lifeline to a company whose blockbuster launch ambitions had hit t | GSK has downgraded a licensing deal for Scynexis' antifungal ibrexafungerp following an ongoing recall of the drug's approved form, Brexafemme. (..)

Pharma 284

Pharma 284